CytomX Therapeutics, Inc.

116 articles with CytomX Therapeutics, Inc.

• CytomX Therapeutics to Announce Third Quarter 2020 Financial Results-Teleconference Scheduled for November 5, 2020, at 5:00 p.m. ET / 2:00 p.m. PT-

  10/29/2020

  CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, plans to report second quarter 2020 financial results on Thursday, November 5, 2020, after the close of U.S. markets.

• CytomX Therapeutics Announces the Planned Retirement of Chief Scientific Officer, W. Michael Kavanaugh, M.D.

  10/6/2020

  CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody ® technology platform, today announced the planned retirement from CytomX of W. Michael Kavanaug

• CytomX Therapeutics Announces New Employment Inducement Grants - Sep 18, 2020

  9/18/2020

  CytomX Therapeutics, Inc. announced that on September 15, 2020, the Company granted nine new employees options to purchase a total of 211,000 shares of the Company’s common stock at an exercise price per share equal to $7.22, which was the closing trading price on September 15, 2020, the date of the grant.

• CytomX Therapeutics to Participate in Upcoming Healthcare Conferences

  9/2/2020

  CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody® therapeutic technology platform, announced today that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in the following virtual healthcare conferences in September.

• CytomX Therapeutics Announces Second Quarter 2020 Financial Results and Provides Business Update Company to Host a Conference Call Today, August 6, 2020, at 5:30 p.m. ET / 2:30 p.m. PT

  8/6/2020

  CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today reported second quarter 2020 financial results and provided a business update.

• CytomX Therapeutics to Participate in the 2020 Wedbush PacGrow Healthcare Conference

  8/4/2020

  CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody® therapeutic technology platform, announced today that Sean McCarthy, D.Phil., president, chief executive officer and chairman, will participate in the 2020 Wedbush PacGrow Virtual Healthcare Conference. Dr. McCarthy will present a Corporate

• CytomX Therapeutics to Announce Second Quarter 2020 Financial Results-Teleconference Scheduled for August 6, 2020, at 5:30 p.m. ET-

  7/28/2020

  CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, plans to report second quarter 2020 financial results on Thursday, August 6, 2020, after the close of U.S. markets. Following the announcement, the company will host a conference call beginning at 5:30 p.m. ET to

• CytomX Therapeutics Announces Preclinical Data from Anti-CTLA-4 Probody Therapeutic Programs Presented by Partner Bristol Myers Squibb at AACR Annual Meeting

  6/22/2020

  Preclinical Data Supports Expanded Therapeutic Index and Provides Rationale for Ongoing Clinical Studies

• CytomX Therapeutics Clinical Programs Highlighted at American Society of Clinical Oncology ASCO20 Virtual Scientific Program

  5/29/2020

  - First Presentation of Clinical Data for CX-2029, a Probody Drug Conjugate,  Directed Against CD71: A Previously Undruggable Target - - Data Updates for CX-2009 Support Phase 2 Investigations in Breast Cancer - - Favorable Tolerability Profile Demonstrated for Anti-PD-L1 and Anti-CTLA-4 Probody Therapeutics - - Company to Host Webcast Today, -

• CytomX Therapeutics to Participate at Upcoming Healthcare Conferences

  5/28/2020

  CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody® therapeutic technology platform, announced today that Sean McCarthy, D.Phil., president, chief executive officer and chairman, will participate in the following virtual healthcare conferences in June.

• CytomX Therapeutics to Host Conference Call and Webcast to Review ASCO ASCO20 Virtual Scientific Program Presentations

  5/26/2020

  CytomX Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, announced it will host a conference call and audio webcast on Friday, May 29, 2020 from 5:00 p.m. to 6:00 p.m. ET / 2:00 p.m. to 3:00 p.m. PT.

• CytomX Therapeutics Announces Details of Presentations at the American Society of Clinical Oncology ASCO20 Virtual Scientific Program

  5/13/2020

  CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, today announced further details of oral and poster presentations at the American Society of Clinical Oncology’s (ASCO) ASCO20 Virtual Scientific Program taking place from May 29 - May 31, 2020.

• CytomX Therapeutics Announces First Quarter 2020 Financial Results and Provides Business Update Company to Host a Conference Call Today, May 7, 2020, at 5:00 p.m. ET / 2:00 p.m. PT

  5/7/2020

  CytomX Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, reported first quarter 2020 financial results and provides a business update.

• CytomX Therapeutics to Present at the 2020 Bank of America Securities Health Care Conference

  5/5/2020

  CytomX Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, announced that Sean McCarthy, D.Phil., president, chief executive officer and chairman, is scheduled to present at the virtual 2020 Bank of America Securities Health Care Conference.

• CytomX Therapeutics Announces Presentations at the 2020 American Society of Clinical Oncology Virtual Scientific Program

  4/29/2020

  7 Abstracts Highlighting CytomX’s Novel Probody Platform Selected for Oral and Poster Presentations

• CytomX Therapeutics Appoints Halley E. Gilbert to Board of Directors

  4/28/2020

  CytomX Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, announced the appointment of Halley E. Gilbert to the company’s board of directors.

• CytomX Therapeutics to Announce First Quarter 2020 Financial Results-Teleconference Scheduled for May 7, 2020, at 5:00 p.m. ET-

  4/27/2020

  CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, plans to report first quarter 2020 financial results on Thursday, May 7, 2020, after the close of U.S. markets. Following the announcement, the company will host a conference call beginning at 5:00 p.m. ET to di

• CytomX Therapeutics Announces Milestone Achievement in AbbVie CD71 Partnership and Provides Update on Impact of COVID-19 on Clinical Stage Pipeline

  3/30/2020

  CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, today announced the achievement of a clinical milestone in conjunction with the CX-2029 program, triggering a $40 million payment from AbbVie to CytomX.

• 

  BioSpace Movers & Shakers, March 27

  3/27/2020

  Pharma and life sciences companies from across the globe provide updates on their pipelines and business.

• CytomX Therapeutics Announces New Employment Inducement Grant - March 25, 2020

  3/25/2020

  CytomX Therapeutics, Inc. announced that on March 23, 2020, the Company granted its recently appointed senior vice president and chief financial officer, Carlos Campoy, an option to purchase a total of 350,000 shares of the Company’s common stock at an exercise price per share equal to $4.93, which was the closing trading price on March 23, 2020, the date of the grant.